

EXECUTIVE SUMMARY

2025-Q3

- 1,816.3 mn Eur, PPP*, 7.3% Sales Growth
- 166.1 mn units, -2.2% Volume Growth
- 2,648,9 mn DOT, 1.9% DOT Growth



YTD (2025-Q3)

- 5,504.0 mn Eur, PPP*, 10.4% Sales Growth
- 523.8 mn units, 0.2% Volume Growth
- 8,205.0 mn DOT, 2.8% DOT Growth


MAT (2025-Q3)

- 7,366.2 mn Eur, PPP*, 11.1% Sales Growth
- 710.8 mn units, 0.3% Volume Growth
- 11,064.1 mn DOT, 2.9% DOT Growth


*PPP-Pharmacy Purchase Price like-for-like growth rates




MARKET SPLIT BY CHANNEL AND STATUS - MAT (2025-Q3), PPP, EUR



MARKET GROWTH BY CHANNEL AND STATUS - PPP, EUR




EXECUTIVE SUMMARY



*PPP-Pharmacy Purchase Price like-for-like growth rates

- ASTRAZENECA
- SUN PHARMA1
- ZENTIVA2
- JOHNSON & JOHNSON
- SERVIER3
- PFIZER
- SANOFI
- HOFFMANN LA ROCHE
- NOVARTIS
- MERCK & CO
- NOVO NORDISK
- ELI LILLY
- VIATRIS
- BAYER AG
- ABBVIE
- MENARINI
- BRISTOL MYERS SQUIBB
- SANDOZ
- GLAXOSMITHKLINE
- RECKITT BENCKISER
- Total Alte



¹ including Terapia
² including Alivogen and Labomed
³ including Egis

TOP 20 BRANDS

Crt. No.	Top 20 brands PRODUCT NAME	Values PPP 2025 - Q3 EUR, mn	Values PPP 2025 - Q3 +/- %	Values PPP YTD(2025 - Q3) EUR, mn	Values PPP YTD(2025 - Q3) +/- %	Values PPP MAT(2025 - Q3) EUR, mn	Values PPP MAT(2025 - Q3) +/- %
	Total market	1,816.3	7.3%	5,504.0	10.4%	7,366.2	11.1%
	Top 20 Rx and OTC drugs	265.6	18.0%	775.6	18.1%	1,027.6	20.5%
1	NUROFEN	23.2	-0.7%	69.4	3.3%	93.9	4.0%
2	RYBELSUS	24.8	32.0%	67.9	55.1%	87.9	61.4%
3	DARZALEX	21.5	14.2%	60.4	17.2%	80.0	20.6%
4	IMBRUVICA	17.2	-3.5%	53.6	0.1%	71.8	0.4%
5	FORXIGA	17.8	30.3%	49.3	29.9%	64.4	32.6%
6	TAGRISSO	14.7	2.0%	44.1	4.8%	59.1	8.3%
7	ASPENTER	12.6	22.9%	37.7	24.3%	48.6	20.7%
8	HEPCLUDEX	12.8	>200%	35.0	>700%	44.6	>900%
9	LYNPARZA	11.1	12.1%	32.9	11.2%	44.1	15.0%
10	VESSEL DUE F	10.8	-4.6%	32.4	6.9%	43.9	10.6%
11	IBRANCE	10.7	-1.4%	32.0	-1.4%	43.4	0.2%
12	DETRALEX	11.1	0.5%	32.6	5.7%	43.3	7.1%
13	VERZENIOS	10.9	17.6%	31.9	25.6%	42.3	34.0%
14	XIGDUO	10.6	5.4%	32.0	14.2%	42.2	16.2%
15	PHESGO	9.6	-3.2%	26.9	-10.0%	37.6	-3.6%
16	ERLEADA	10.2	48.6%	28.9	57.8%	37.1	64.7%
17	SORTIS	9.4	10.5%	27.8	12.3%	36.4	9.9%
18	VENCLYXTO	8.7	-4.9%	27.0	7.0%	36.0	8.9%
19	CLEXANE	8.6	-6.2%	26.9	-13.1%	35.6	-11.3%
20	JARDIANCE	9.2	22.6%	27.0	32.6%	35.5	40.1%

CVR drugs	15.4	41.7%	47.0	-9.0%	66.0	-11.0%
CV drugs	266.2	16.4%	778.1	20.3%	1,018.6	21.8%

TOP 20 CORPORATIONS

Crt. No.	CORPORATION	Values PPP 2025 - Q3 EUR, mn	Values PPP 2025 - Q3 +/- %	Values PPP YTD(2025 - Q3) EUR, mn	Values PPP YTD(2025 - Q3) +/- %	Values PPP MAT(2025 - Q3) EUR, mn	Values PPP MAT(2025 - Q3) +/- %
	Total	1,816.3	7.3%	5,504.0	10.4%	7,366.2	11.1%
1	ASTRAZENECA	99.5	13.6%	296.5	17.9%	393.3	20.8%
2	SUN PHARMA ¹	81.2	5.9%	247.6	10.0%	329.9	9.3%
3	ZENTIVA ²	75.2	1.4%	227.8	3.7%	306.5	4.7%
4	JOHNSON & JOHNSON	70.0	9.4%	203.8	9.2%	271.2	10.6%
5	SERVIER ³	64.2	0.6%	191.2	4.4%	254.3	4.9%
6	PFIZER	60.9	5.4%	180.8	5.4%	242.4	6.3%
7	SANOFI	54.7	4.4%	162.3	4.4%	222.4	4.4%
8	HOFFMANN LA ROCHE	55.8	10.9%	165.2	12.0%	221.5	16.0%
9	NOVARTIS	54.0	8.1%	164.2	11.4%	219.5	13.4%
10	MERCK & CO	55.7	16.1%	162.0	20.5%	214.2	24.3%
11	NOVO NORDISK	52.4	9.0%	148.9	3.8%	196.4	4.6%
12	ELI LILLY	52.5	45.3%	136.8	33.3%	173.8	30.3%
13	VIATRIS	41.0	0.9%	125.7	2.5%	172.1	2.0%
14	BAYER AG	34.6	1.3%	102.5	-1.2%	137.4	-0.8%
15	ABBVIE	32.8	-4.9%	98.0	8.1%	131.9	8.6%
16	MENARINI	32.8	4.7%	99.2	10.4%	131.5	10.0%
17	BRISTOL MYERS SQUIBB	34.0	15.8%	97.7	14.7%	130.2	17.2%
18	SANDOZ	26.6	-5.7%	87.0	0.8%	118.6	4.2%
19	GLAXOSMITHKLINE	29.1	4.1%	87.8	6.3%	117.7	6.1%
20	RECKITT BENCKISER	27.0	-2.8%	83.1	2.9%	113.6	4.7%
	All others	782.5	7.1%	2,435.9	11.9%	3,267.8	12.2%